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greater LOS and 32.3% greater ICU LOS (both p< 0.001) than patients not receiving 
blood. In patients who received blood, total cost of hospital stay was 22.7% greater 
including blood product cost and 21.7% greater excluding blood product cost (both 
p< 0.001). ConClusions: Preventing or rapidly controlling bleeding in patients 
undergoing complex cardiac surgery would likely reduce patient risk and avoid 
elevated costs of hospitalization.
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objeCtives: Syncope, defined as a transient loss of consciousness that leads to a 
spontaneous recovery without consequences, is very prevalent. It is known that syn-
cope related admissions (principal diagnosis) are associated with a high cost burden 
for the Spanish National Health System, but little is known about the number of 
hospitalisations due to injuries caused by the fall (secondary diagnosis). The objec-
tive of this study was to estimate the burden and cost of syncope from the Spanish 
Health Care System perspective. Methods: Admissions with a primary diagnosis 
of syncope and admissions for injuries and pacemaker/defibrillator implantations 
where syncope was coded as a secondary diagnosis were analysed. The source of 
data was the Spanish Basic Minimum Data Set and the period 2001-2010. Results: 
The annual incidence of syncope-related admission was 4.22 cases/10,000 inhab. 
The annual average number of admissions was 15,703, including 77.5% syncope as a 
primary diagnosis. The total annual cost of syncope related admissions was € 46mill, 
from which a 46.4% was associated to injuries where syncope was coded as a sec-
ondary diagnosis. The average cost of a patient admitted with syncope as a primary 
and secondary diagnosis was € 2,062 (min € 1,556 – max € 28,772) and € 5,996 (min € 719 
– max € 26,940) respectively. The average length of stay for patients with syncope as a 
primary and secondary diagnosis was 5.17 and 9.33 days respectively. ConClusions: 
Syncope has an important cost burden resulted from the high number of hospitalisa-
tions and the length of stay associated. The cost of a patient admitted with syncope 
as a secondary diagnosis was nearly 3 times higher than a patient with a primary 
diagnosis of syncope. It is important to implement health strategies to diagnose 
these patients in order to assure an efficient management of the available resources.
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objeCtives: The present study aimed to investigate the cost of non-valvular atrial 
fibrillation (NVAF) management in Hong Kong. Methods: We analyzed consecu-
tive patients with documented NVAF enrolled in the Prince of Wales Hospital Atrial 
Fibrillation Registry between February 2013 and February 2014.. Patient clinical char-
acteristics, prescribed therapies and adverse clinical events were extracted from the 
hospital electronic Clinical Management System. One-year direct health care costs 
including costs of medications, accident and emergency admissions, hospitalizations, 
clinical visits, coagulation tests and computed tomography of brain scans were esti-
mated from a health care provider perspective. Results: Of 534 NVAG patients, 45.9% 
were male with a mean age of 75.8±10.2 years. The average CHADS2, CHAsDSsVASc 
and HASBLED scores were 2.44±1.39,4. 12±1.77 and 3.26±1.09, respectively. 66.7% of 
patients were taking rate control medications only. Patients taking both rate and 
rhythm control medications were associated with the highest rate of hospitaliza-
tions due to poor AF control (28.2%) when compared to using neither rate or rhythm 
control drugs, rate control or rhythm control groups (p < 0.0005). The overall use of 
anticoagulants including both warfarin and new oral anticoagulants was 66.9%. The 
main reason for patients with CHADS2 score ≥ 2 not receiving anticoagulant was 
patient refusal (20%) and physicians’ opinion (40%). The one-year median cost of 
managing patients with stroke was higher than those without stroke (Euro$ 5521.2 
versus Euro$ 1075.2) from the health care provider perspectives during the study 
period. ConClusions: Majority of NVAF patients in Hong Kong were prescribed 
rate control medications only. The clinical use of antithrombotic therapy for stroke 
prevention was more conservative than guideline recommendations. It was more 
costly (5 times more) to manage patients with stroke than patients without stroke.
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objeCtives: There is a high risk of recurring cardiovascular (CV) events in patients 
post myocardial infarction (MI) despite the current standard of care (SoC). The aim 
of this study was to estimate the current economic burden of CV events for patients 
after having an MI event. Methods: A lifetime markov model was developed from 
a UK health care perspective to capture progression post-MI. Recurrent MI, stroke 
and CV deaths were the major CV events captured. A comparison of cost (2012 UK£) 
and outcomes in terms of QALYs and life years (LYs) was made between the cur-
rent scenario of patients receiving SOC and a hypothetical scenario where post-MI 
patients had no subsequent CV events. All cost and outcomes were discounted at 
3.5% per annum. Results: The current cumulative lifetime event rate of non-fatal 
MI, non-fatal stroke and CV death post-MI was estimated to be 0.432,0. 06 and 
0.42/patient respectively. The total lifetime cost was estimated to be £6,926/post-MI 
patient without CV events, which was 31% lower than the current estimated cost 
of £9,959/post-MI patient. At current rates of CV events there was an incremental 
lifetime loss of 4.3 LYs/patient and 3.5 QALYs/patient when compared to the hypo-
thetical scenario where patients had no CV events. Considering the prevalence of 
MI to be 1.5 million, the economic burden posed by MI patients over lifetime if they 
the direct medical expenditures on the final outputs. ConClusions: The treatment 
of disabled superficial femoral artery was compared from chosen clinical outputs, 
economic expenditures and cost-effectiveness. On this basis, the recommendation 
was set for choosing the most effective treatment.
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objeCtives: Stroke generates an important socioeconomic burden and heavy 
hospital expenses. The objective of this study was to evaluate the impact of delay 
to manage stroke for patients transported by Mobile Intensive Care Units (MICU) 
in outcomes and early hospital costs. Cost of management and NHISS (National 
Institute of Health Stroke Score) score regression at patient discharge have been 
described for three different stroke management time groups. Methods: A retro-
spective study was conducted from a database containing records of 427 patients 
diagnosed with stroke. Patients were classified as “short delay” (stroke managed 
within 45 minutes), “medium delay” (45 minutes to 2 hours) and “long delay” (above 
2 hours). 3 homogenous groups of 100 patients were established, adjusted on age, 
gender, stroke mechanism (ischemic or hemorrhagic), NIHSS score and comorbidity. 
Hospital Database (PMSI - French National Hospital Information Systems Program) 
recorded information between 2004 and 2013. ResultsThe number of deaths was 
respectively 17 for « short delay », 25 for « medium delay » and 42 for « long delay ». 
The average cost for one hospital stay for stroke was € 15,812 for the « short delay 
» group, € 20,639 for « medium delay » and € 20,184 for « long delay ». “Short delay” 
treated patients retrieve an average of 8.41 points compared to 1.87 for “long delay” 
patients. ConClusions: These results show a correlation between the delay in 
managing stroke and early hospital costs and improvement of NIHSS scores. These 
results are part of a study performed through the PMSI database aiming at calculat-
ing the average cost of retrieving one-point NIHSS impairment. They underline the 
importance of an early treatment of stroke.
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objeCtives: Atrial fibrillation (AF) is associated with numerous cardiovascu-
lar (CV) complications. The objective of this study was to estimate the national 
annual burden of CV complications in patients with AF in hospitals. Methods: 
All patients hospitalized in 2012 with a diagnosis of AF were identified from the 
French National public/private hospital database (PMSI). Comorbidities and medical 
data were collected during a 5-year look-back period and used to calculate stroke 
risk score (CHA2DS2-VASc). Reasons for CV-related hospitalization, emergency 
admission, rehabilitation and death at discharge were described. Costs of acute 
care were determined using Diagnosis Related Groups and corresponding tariffs 
(2012 Euros). Results: In total, 533,044 AF patients were hospitalized for any rea-
son. Mean age was 78.0(±11.4) years, 53% were males and mean CHA2DS2-VASc 
score was 4.0(±1.8). CV-related hospitalizations occurred in 267,681 patients: 34% 
for AF management care, 28% for heart failure, 8% for strokes, 7% for other ischemic 
heart diseases, 5% for vascular diseases, 4% for transient ischemic attacks and 
systemic embolisms, 2% for bleedings and 12% for other CV reasons. In CV-related 
hospitalizations, 45% of patients required emergency admission, especially patients 
hospitalized for strokes (75%) and for bleedings (67%). Death at hospital occurred in 
6% of patients with a CV-related hospitalization: 17% in patients with strokes and 
10% in patients with bleedings. Rehabilitation was needed for 34% patients with 
non-fatal strokes with a mean length of 48 days. The annual total cost (acute care 
and rehabilitation) for all hospitalized CV events during the year 2012 was € 1.94 bil-
lion. Among this, heart failure represented € 518m, AF management € 306m, strokes 
€ 291m and hemorrhages € 48m. ConClusions: A half-million AF patients were 
hospitalized in 2012 in France. CV-related hospitalizations involved over a quarter-
million AF patients for a global burden of almost € 2 billion.
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objeCtives: In complex cardiac surgery there is a high demand for blood/blood 
products. Their administration can be costly. Our goal was to assess the cost of 
care and outcomes for complex cardiac surgery patients based on bleeding sta-
tus. Methods: Patients > 18 years, discharged between January 2010 and December 
2012, were identified in the Premier Hospital Database based on ICD9 codes and 
categorized as having received blood/blood products or not. Patients who received 
blood products prior to the day of surgery were excluded. Differences in treatment 
costs and outcomes were assessed using univariate analysis and multivariate mod-
eling. Results: A total of 463,734 patients (82,832 Bleeding; 380,902 Non-Bleeding) 
were included. Patients who received blood were older (> 65 years: 62.3% vs. 49.8%), 
sicker (Charlson Comorbidity Index > 3: 22.5% vs. 15.4%), with greater rates of cer-
ebrovascular disease (10.2% vs. 4.3%), PVD (18.2% vs. 9.4%), CHF (33.0% vs. 18.6%), 
renal dx (20.9% vs. 13.5%) and CPD (25.3% vs. 18.7%) than those who did not. Models 
adjusting for patient factors showed that patients who received blood were 4.54 
times as likely to be admitted to the ICU, 3.40 times as likely to die and 4.59 times as 
likely to be readmitted for bleeding within 30 days (all p< 0.001). They also had 49.1% 
